The Optimal Time to Initiate HIV Therapy Under Ordered Health States

References

• Aalen O. O., Farewell V. T., De Angelis D., Day N. E., Gill O. N. A Markov model for HIV disease progression including the effect of HIV diagnosis and treatment: Application to AIDS prediction in England and Wales. Statist. Medicine (1997) 16:2191–2210Crossref, Google Scholar
• Ahdieh-Grant L., Yamashita T. E., Phair J. P., Detels R., Wolinsky S. M., Margolick J. B., Rinaldo C. R., Jacobson L. P. When to initiate highly active antiretroviral therapy: A cohort approach. Amer. J. Epidemiology (2003) 157(8):738–746Crossref, Google Scholar
• AIDS Education Global Information System Opportunistic infections. (2006) . Retrieved June 1, 2006, www.aegis.com/topics/oiGoogle Scholar
• Alagoz O., Bryce C. L., Shechter S., Schaefer A., Chang C. C. H., Angus D. C., Roberts M. S. Incorporating biological natural history in simulation models: Empirical estimates of the progression of end-stage liver disease. Medical Decision Making (2005) 25(6):620–632Crossref, Google Scholar
• Alvarez-Ramirez J., Meraz M., Velasco-Hernandez J. X. Feedback control of the chemotherapy of HIV. Internat. J. Bifurcation and Chaos (2000) 10(9):2207–2219Crossref, Google Scholar
• Anastos K., Barrón Y., Miotti P., Weiser B., Young M., Hessol N., Greenblatt R. M., Cohen M., Augenbraun M., Levine A., Muñoz A.for the Women's Interagency HIV Study Collaborative Study Group. Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Archives Internal Medicine (2002) 162(17):1973–1980Crossref, Google Scholar
• Anderson R. N. Method for constructing annual U.S. life tables. National Center for Health Statist.: Vital Health Statist. (1999) 2(129):1–36Google Scholar
• Bangsberg D. R., Perry S., Charlebois E. D., Clark R. A., Robertson M., Zolopa A. R., Moss A. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (2001) 15(9):1181–1183Crossref, Google Scholar
• Barlow R. E., Proschan F.Mathematical Theory of Reliability (1965) (John Wiley & Sons, Inc., New York) Google Scholar
• Bayoumi A. M., Redelmeir D. A. Preventing mycobacterium avium complex in patients who are using protease inhibitors: A cost-effectiveness analysis. Quality Life Res. (1998) 12(12):1503–1512Google Scholar
• Bayoumi A. M., Redelmeir D. A. Economic methods for measuring the quality of life associated with HIV infection. Quality Life Res. (1999) 8:471–480Crossref, Google Scholar
• Beck R. J., Pauker S. G. The Markov process in medical prognosis. Medical Decision Making (1983) 3:419–458Crossref, Google Scholar
• Bellman R. E.Dynamic Programming (1957) (Princeton University Press, Princeton, NJ) Google Scholar
• Bennett M., Indyk D., Golub S. Adherence re-framed in the BIG picture: A qualitative ecological perspective on HIV+ patients and protease inhibitors. Program and Abstracts Twelfth World AIDS Conf. (1998) (Marathon Multimedia, Geneva, Switzerland) . Abstract 32365Google Scholar
• Berman S. M., Galambos J., Gani J. Optimal timing of antiretroviral therapy in HIV infection. Studies in Applied Probability: Essays in Honour of Lajos Takács (1994) (Applied Probability Trust, Sheffield, UK) 3–15Google Scholar
• Berman S. M., Dubin N., Jewell N. P., Dietz K., Farewell V. T. Is earlier better for AZT therapy in HIV infection? A mathematical model. AIDS Epidemiology: Methodological Issues (1992) (Birkhäuser, Boston) 366–383Crossref, Google Scholar
• Bertsekas D. P., Tsitsiklis J. N.Neuro-Dynamic Programming (1996) (Athena Scientific, Belmont, MA) Google Scholar
• Braithwaite R. S. Personal correspondence. (2006) Google Scholar
• Braithwaite R. S., Chang C. C., Gilbert C., Goetz M., Koppenhaver R., Rodriguez M., Schaefer A. J., Shechter S. M., Justice A. C. Estimated life expectancy and quality-adjusted life-years of HIV patients with alternative CD4 thresholds for initiating antiretroviral therapy. Ann. Internal Medicine (2008) . ForthcomingCrossref, Google Scholar
• Brandt M. E., Chen G. Feedback control of a biodynamical model of HIV-1. IEEE Trans. Biomedical Engrg. (2001) 48(7):754–759Crossref, Google Scholar
• Brundage J. F., McNeil J. G., Miller R. N., Gardner L. I., Harrison S. M., Hawks C., Craig D. B., Redfield R., Burke D. S.the U.S. Army Retrovirus Research Group. The current distribution of CD4+ T-lymphocyte counts among adults in the United States with human immunodeficiency virus infections: Estimates based on the experience of the U.S. Army. J. Acquired Immune Deficiency Syndromes (1990) 3:92–94Google Scholar
• Butler S., Kirschner D., Lenhart S., Arino D., Axelrod D., Kimmel M. Optimal control of chemotherapy affecting the infectivity of HIV. Advances in Mathematical Populations Dynamics: Molecules, Cells, Man (1997) (World Scientific Press, Singapore) 557–569Google Scholar
• Carmona A., Knobel H., Guelar A., Grau S., Mateau de Antonio J., Lopez-Colomes J. L., Saballs P. Factors influencing survival in HIV infected patients treated with HAART. Thirteenth Internat. AIDS Conf. (2000) Durban, South AfricaAbstract TuOrB417Google Scholar
• Chaisson R. E., Keruly J. C., Moore R. D. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. JAMA (2000) 284(24):3128–3129Crossref, Google Scholar
• Chesney M. A. Adherence to HAART regimens. AIDS Patient Care and STDs (2003) 17(4):169–177Crossref, Google Scholar
• Cleary P. D., Fowler F. J., Weissman J., Massagli M. P., Wilson I., Seage G. R., Gatsonis C., Epstein A. Health-related quality of life in persons with acquired immune deficiency syndrome. Medical Care (1993) 31(7):569–580Crossref, Google Scholar
• Cohen C. J., Boyle B. A. Antiretroviral therapy: The “when to start” debates. Clinical Infectious Diseases (2004) 39(11):1705–1708Crossref, Google Scholar
• Collett D.Modelling Survival Data in Medical Research (1994) (Chapman & Hall, London, UK) Crossref, Google Scholar
• Community Programs for Clinical Research on AIDS SMART: Strategies for Management of Anti-Retroviral Therapy. (2002) . Retrieved December 6, 2005, www.smart-trial.orgGoogle Scholar
• Copfer A. E., Ampel N. M., Hughes T. E., Gregor K. J., Dols C. L., Coons S. J., Colgan K., Wu A. W. The use of two measures of health-related quality of life in HIV-infected individuals: A cross-sectional comparison. Quality Life Res. (1996) 5:281–286Crossref, Google Scholar
• Cox D. R. Regression models and life tables (with discussion). J. Roy. Statist. Soc., Ser. B (1972) 34:187–220Google Scholar
• Craig B. A., Sendi P. P. Estimation of the transition matrix of a discrete-time Markov chain. Health Econom. (2002) 11:33–42Crossref, Google Scholar
• Craig B. A., Fryback D. G., Klein R., Klein B. E. K. A Bayesian approach to modelling the natural history of a chronic condition from observations with intervention. Statist. Medicine (1999) 18:1355–1371Crossref, Google Scholar
• Dal Maso L., Gava M., Pezzotti P., Torelli N., Franceschi S., Giovannia R.for the Italian Seroconversion Study. Markov models for HIV disease progression: An unverified assumption. J. Acquired Immune Deficiency Syndromes (2000) 25(5):466–468Crossref, Google Scholar
• De Gruttola V., Wulfsohn M., Fischl M. A., Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J. Acquired Immune Deficiency Syndromes and Human Retrovirology (1993) 6:359–365Google Scholar
• Drummond M. F., O'Brien B., Stoddart G. L., Torrance G. W.Methods for the Economic Evaluation of Health Care Programmes (1997) (Oxford University Press, Oxford, UK) Google Scholar
• Duran S., Spire B., Raffi F., Walter V., Bouhour D., Journot V., Cailleton V., Leport C., Moatti J. P.the APROCO Cohort Study Group. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clinical Trials (2001) 2(1):38–45Crossref, Google Scholar
• Egger M., May M., Chene G., Phillips A. N., Ledergerber B., Dabis F., Costagliola D., Monforte A. D'Arminio, de Wolf F., Reiss P., Lundgren J. D., Justice A. C., Staszewski S., Leport C., Hogg R. S., Sabin C., Gill M. J., Salzberger B., Sterne J. A. C.the ART Cohort Collaboration. Progonosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. The Lancet (2002) 360(9327):119–129Crossref, Google Scholar
• Eldred L. J., Wu A. W., Chaisson R. E., Moore R. D. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J. Acquired Immune Deficiency Syndromes and Human Retrovirology (1998) 18:117–125Crossref, Google Scholar
• Fister K. R., Lenhart S., McNally J. S. Optimizing chemotherapy in an HIV model. Electronic J. Differential Equations (1998) 32:1–12 http://ejde.math.txstate.edu/Google Scholar
• Freedberg K. A., Scharfstein J. A., Seage G. R., Losina E., Weinstein M. C., Craven D. E., Paltiel A. D. The cost effectiveness of preventing AIDS-related opportunistic infections. JAMA (1998) 279(2):130–136Crossref, Google Scholar
• Freedberg K. A., Losina E., Weinstein M. C., Paltiel A. D., Cohen C. J., Seage G. R., Craven D. E., Zhang H., Kimmel A. D., Goldie S. J. The cost effectiveness of combination antiretroviral therapy for HIV disease. New England J. Medicine (2001) 344(11):824–831Crossref, Google Scholar
• Gelber R. D., Lenderking W. R., Cotton D. J., Cole B. F., Fischl M. A., Goldhirsch A., Testa M. A. Quality-of-life evaluation in clinical trials of zidovudine therapy in patients with mild symptomatic HIV infection. Ann. Internal Medicine (1992) 116(12, Part 1):961–966Crossref, Google Scholar
• Gentleman R. C., Lawless J. F., Lindsey J. C., Yan P. Multi-state Markov models for analysing incomplete disease history data with illustrations for HIV disease. Statist. Medicine (1994) 13:805–821Crossref, Google Scholar
• Gir E., Pratt R., Bunch E. H., Holzemer W. L. Adherence to anti-retroviral therapy: A four country comparison. Program and Abstracts Twelfth World AIDS Conf. (1998) (Marathon Multimedia, Geneva, Switzerland) . Abstract 60129Google Scholar
• Gold M. R., Patrick D. L., Torrance G. W., Fryback D. G., Hadorn D. C., Kamlet M. S., Daniels N., Weinstein M. C., Gold M. R., Siegel J. E., Russell L. B., Weinstein M. C. Identifying and valuing outcomes. Cost-Effectiveness in Health and Medicine (1996) (Oxford University Press, New York) 82–134Google Scholar
• Green P. J., Silverman B. W.Nonparametric Regression and Generalized Linear Models: A Roughness Penalty Approach (1994) (Chapman & Hall, London, UK) Crossref, Google Scholar
• Harrington M., Carpenter C. J. Hit HIV hard, but only when necessary. The Lancet (2000) 355:2147–2152Crossref, Google Scholar
• Haubrich R. H., Little S. J., Currier J. S., Forthal D. N., Kemper C. A., Beall G. N., Johnson D., Dube M. P., Hwang J. Y., McCutchan J. A.the California Collaborative Treatment Group. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS (1999) 13:1099–1107Crossref, Google Scholar
• Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann. Internal Medicine (2000) 132:306–311Crossref, Google Scholar
• Ho D. D. Time to hit HIV, early and hard. New England J. Medicine (1995) 333:450–451Crossref, Google Scholar
• Hoffman C., Mulcahy F., Hoffman C., Rockstroh J., Kamps B. S. When to start HAART. HIV Medicine (2007) (Flying Publisher, Paris, France) . www.hivmedicine.comGoogle Scholar
• Hogg R. S., Yip B., Chan K. J., Wood E., Craib K. J. P., O'Shaughnessy M. V., Montaner J. S. G. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA (2001) 286(20):2568–2577Crossref, Google Scholar
• Holmberg S. D., Palella F. J., Lichtenstein K. A., Havlir D. A. The case for earlier treatment of HIV infection. Clinical Infectious Diseases (2004) 39:1699–1704Crossref, Google Scholar
• Holtgrave D. R., Qualis N. L. Threshold analysis and HIV prevention programs. Medical Decision Making (1995) 15:311–317Crossref, Google Scholar
• Isaman D. J. M., Herman W. H., Brown M. B. A discrete-state discrete-time model using indirect observation. Statist. Medicine (2006) 25:1035–1049Crossref, Google Scholar
• Jeffrey A. M., Xia X., Craig I. K. When to initiate HIV therapy: A control theoretic approach. IEEE Trans. Biomedical Engrg. (2003) 50(11):1213–1220Crossref, Google Scholar
• Joshi H. R. Optimal control of an HIV immunology model. Optimal Control Appl. Methods (2002) 23:199–213Crossref, Google Scholar
• Justice A. C., Wagner J. H., Fusco G. P. HIV survival: Liver function tests independently predict survival. Program and Abstracts XIV Internat. AIDS Conf. (2002) Barcelona, SpainAbstract MoOrB1058Google Scholar
• Keeler E. B., Cretin S. Discounting of life-saving and other nonmonetary effects. Management Sci. (1983) 29:300–306Link, Google Scholar
• King J. T., Justice A. C., Roberts M. S., Chang C. C. H., Fusco J. S. Long term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Medical Decision Making (2003) 23:9–20Crossref, Google Scholar
• Kirschner D., Webb G. F. A model for treatment strategy in the chemotherapy of AIDS. Bull. Math. Biol. (1996) 58:367–390Crossref, Google Scholar
• Kirschner D., Lenhart S., Serbin S. Optimal control of the chemotherapy of HIV. J. Math. Biol. (1997) 35:775–792Crossref, Google Scholar
• Law A. M., Kelton W. D.Simulation Modeling and Analysis (2000) 3rd ed.(McGraw-Hill, New York) Google Scholar
• Lenert L. A., Feddersen M., Sturley A., Lee D. Adverse effects of medications and tradeoffs between length of life and quality of life in human immunodeficiency virus infection. Amer. J. Medicine (2002) 113(3):229–232Crossref, Google Scholar
• Lepri A. C., Phillips A. N., Monforte A. d'Arminio, Castelli F., Antinori A., de Luca A., Pezzotti P., Alberici F., Cargnel A., Grima P., Piscopo R., Prestileo T., Scalise G., Vigevani M., Moroni M.for the ICONA study group. When to start highly active antiretroviral therapy in chronically HIV-infected patients: Evidence from the ICONA study. AIDS (2001) 15(8):983–990Crossref, Google Scholar
• Lichtenstein K., Armon C., Buchacz K., Moorman A., Wood K., Brooks J.the HIV Outpatient Study Group. Early, uninterrupted ART is associated with improved outcomes and fewer toxicities in the HIV Outpatient Study (HOPS). Thirteenth Conf. Retroviruses and Opportunistic Infections (2006) Denver, ColoradoAbstract 769Google Scholar
• Longini I. M. Modeling the decline of CD4+ T-lymphocyte counts in HIV-infected individuals. J. Acquired Immune Deficiency Syndromes (1990) 3:930–931Google Scholar
• Longini I. M., Clar W. S., Gardner L. I., Brundage J. F. The dynamics of CD4+ T-lymphocyte decline in HIV-infected individuals: A Markov modeling approach. J. Acquired Immune Deficiency Syndromes (1991) 4:1141–1147Google Scholar
• Mauskopf J., Kitahata M., Kauf T., Richter A., Tolson J. HIV antitretoviral treatment: Early versus later. J. Acquired Immune Deficiency Syndromes (2005) 39:562–569Google Scholar
• Mellors J. W., Munoz A., Giorgi J. V., Margolick J. B., Tassoni C. J., Gupta P., Kingsley L. A., Todd J. A., Saah A. J., Detels R., Phair J. P., Rinaldo C. R. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Internal Medicine (1997) 126:946–954Crossref, Google Scholar
• Mrus J. M., Schackman B. R., Wu A. W., Freedberg K. A., Tsevat J., Yi M. S., Zackin R. Variations in self-rated health among patients with HIV infection. Quality Life Res. (2006) 15:503–514Crossref, Google Scholar
• National Institutes of Health Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. (2005) . http://aidsinfo.nih.govGoogle Scholar
• O'Shaughnessy M., Montaner J., Hogg R., Yip B., Chan K., Craib K. To start or not to start? Diminished effectiveness of anti-retroviral therapy among patients initiating therapy with CD4+ cell counts below 200/mm3. Thirteenth Internat. AIDS Conf. (2000) Durban, South AfricaAbstract LbPeB7050Google Scholar
• Owens D. K., Cardinalli A. B., Nease R. F. Physicians' assessments of the utility of health states associated with human immunodeficiency virus infection. Quality Life Res. (1997) 6:77–86Crossref, Google Scholar
• Palella F. J., Delaney K. M., Moorman A. C. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England J. Medicine (1998) 338:853–860Crossref, Google Scholar
• Palella F. J., Deloria-Knoll M., Chmiel J. S., Moorman A. C., Wood K. C., Greenberg A. E., Holmberg S. D., Havlir D. A.the HIV Outpatient Study (HOPS) Investigators. Survival benefit of initiating antitretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann. Internal Medicine (2003) 138:620–626Crossref, Google Scholar
• Paltiel A. D., Scharfstein J. A., Seage G. R., Losina E., Goldie S. J., Weinstein M. C., Craven D. E., Freedberg K. A. A Monte Carlo simulation of advanced HIV disease: Application to prevention of CMV infection. Medical Decision Making (1998) 18:S93–S105Crossref, Google Scholar
• Paterson D. L., Swindells S., Mohr J., Brester M., Vergis E. N., Squier C., Wagener M. M., Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Internal Medicine (2000) 133:21–30Crossref, Google Scholar
• Phillips A. N., Lepri A. C., Lampe F., Johnson M., Sabin C. A. When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS (2003) 17(3):1863–1869Crossref, Google Scholar
• Phillips A. N., Staszewski S., Weber R., Kirk O., Francioli P., Miller V., Vernazza P., Lundgren J. D., Ledergerber B.for the Swiss HIV Cohort Study and the Frankfurt HIV Clinic Cohort and the EuroSIDA Study Group. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 286(20):2560–2567Crossref, Google Scholar
• Poundstone K. E., Chaisson R. E., Moore R. D. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS (2001) 15(9):1115–1123Crossref, Google Scholar
• Puterman M. L.Markov Decision Processes (1994) (John Wiley and Sons, New York) Crossref, Google Scholar
• Revicki D. A., Wu A. W., Murray M. I. Change in clinical status, health status, and health utility outcomes in HIV infected patients. Medical Care (1995) 33:AS173–AS182Google Scholar
• Richter A., Hauber B., Simpson K., Mauskopf J. A., Yin D. A Monte Carlo simulation of AIDS treatment regimens. Pharmacoeconomics (2002) 20(4):215–224Crossref, Google Scholar
• Roberts M. S., Sonnenberg F. A., Chapman G. B., Sonnenberg F. A. Decision modeling techniques. Decision Making in Health Care: Theory, Psychology, and Applications (2000) (Cambridge University Press, Cambridge, UK) 20–65Google Scholar
• Ross S. M.Introduction to Stochastic Dynamic Programming (1983) (Academic Press, San Diego) Google Scholar
• Sanders G. D., Owens D. K., Padian N., Cardinalli A. B., Sullivan A. N., Nease R. F. A computer-based interview to identify HIV risk behaviors and to assess patient preferences for HIV-related health states. Proc. Annual Sympos. Comput. Appl. Medical Care (1994) Washington, DC(Hanley & Belfus Inc., Philadelphia) 20–24Google Scholar
• Schackman B. R., Freedberg K. A., Weinstein M. C., Sax P. E., Losina E., Zhang H., Goldie S. J. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Archives of Internal Medicine (2002a) 162:2478–2486Crossref, Google Scholar
• Schackman B. R., Goldie S. J., Freedberg K. A., Losina E., Brazier J., Weinstein M. C. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Medical Decision Making (2002b) 22:27–38Crossref, Google Scholar
• Schaefer A. J., Bailey M. D., Shechter S. M., Roberts M. S., Brandeau M., Sainfort F., Pierskalla W. Modeling medical treatment using Markov decision processes. Operations Research and Health Care: A Handbook of Methods and Applications (2004) (Kluwer Academic Publishers, Boston) 597–616Google Scholar
• Selwyn P. A., Rivard M. Palliative care for AIDS: Challenges and opportunities in the era of highly active antiretroviral therapy. J. Palliative Medicine (2003) 6(3):475–487Crossref, Google Scholar
• Sendi P. P., Bucher H. C., Craig B. A., Pfluger D., Battegay M.for the Swiss HIV Cohort Study. Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. J. Acquired Immune Deficiency Syndromes and Human Retrovirology (1999) 20:376–381Crossref, Google Scholar
• Shechter S. M. When to initiate, when to switch, and how to sequence HIV therapies: A Markov decision process approach. (2006) . Ph.D. dissertation, University of Pittsburgh, PittsburghGoogle Scholar
• Shernoff M., Smith R. A. HIV treatments: A history of scientific advance. (2001) . Retrieved April 26, 2006, www.thebody.com/bp/jul01/treatments.htmlGoogle Scholar
• Sonnenberg F. A., Beck R. J. Markov models in medical decision making: A practical guide. Medical Decision Making (1993) 13(4):322–328Crossref, Google Scholar
• Sterling T. R. Antiretroviral therapy: When to start and what to start with. The Hopkins HIV Rep. (2002) 14(5):1–4Google Scholar
• Sterling T. R., Chaisson R. E., Moore R. D. Initiation of highly active antiretroviral therapy at CD4 T lymphocyte counts of ≥350 cells/mm3: Disease progression, treatment durability, and drug toxicity. Clinical Infectious Diseases (2003a) 36(6):812–815Crossref, Google Scholar
• Sterling T. R., Chaisson R. E., Keruly J., Moore R. D. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: Longer follow-up of an observational chort study. J. Infectious Diseases (2003b) 188(11):1659–1665Crossref, Google Scholar
• Stine G. J.AIDS Update, 2003: An Annual Overview of Acquired Immune Deficiency Syndrome (2003) (Prentice Hall, Upper Saddle River, NJ) Google Scholar
• Tashima K. T., Hogan J. W., Gardner L. I., Korkontzelou C., Schoenbaum E. E., Schuman P., Rompalo A., Carpenter C. C. J. A longitudinal analysis of hospitalization and emergency department use among human immunodeficiency virus-infected women reporting protease inhibitor use. Clinical Infectious Diseases (2001) 33:2055–2060Crossref, Google Scholar
• Tebas P., Henry K., Nease R., Murphy R., Phair J., Powderly W. G. Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate long-term implications of therapy. AIDS (2001) 15:591–599Crossref, Google Scholar
• Tengs T. O., Lin T. H. A meta-analysis of utility estimates for HIV/AIDS. Medical Decision Making (2002) 22:475–481Crossref, Google Scholar
• Tengs T. O., Wallace A. One thousand health-related quality-of-life estimates. Medical Care (2000) 38(6):583–637Crossref, Google Scholar
• Tsevat J., Sherman S. N., McElwee J. A., Mandell K. L., Simbartl L. A., Sonnenberg F. A., Fowler F. J. The will to live among HIV-infected patients. Ann. Internal Medicine (1999) 131(3):194–198Crossref, Google Scholar
• Tsevat J., Solzan J. G., Kuntz K. M., Ragland J., Currier J. S., Sell R. L., Weinstein M. C. Health values of patients infected with human immunodeficiency virus: Relationship to mental health and physical functioning. Medical Care (1996) 34(1):44–57Crossref, Google Scholar
• UNAIDS UNAIDS/WHO AIDS epidemic update: December 2005. (2005) . Retrieved April 19, 2006, http://www.unaids.org/epi/2005/doc/report.aspGoogle Scholar
• Veterans Aging Cohort Study (2005) . Retrieved December 6, 2005, http://www.vacohort.org/Google Scholar
• Wein L. M., D'Amato R. M., Perelson A. S. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J. Theoret. Biol. (1998) 192(1):81–98Crossref, Google Scholar
• Wein L. M., Zenios S. A., Nowak M. A. Dynamic multidrug therapies for HIV: A control theoretic approach. J. Theoret. Biol. (1997) 185:15–29Crossref, Google Scholar
• Weinstein M. C., Stason W. B. Foundations of cost-effectiveness analysis for health and medical practices. New England J. Medicine (1977) 296:716–721Crossref, Google Scholar
• Welton N. J., Ades A. E. Estimation of Markov chain transition probabilities and rates from fully and partially observed data: Uncertainty progagation, evidence synthesis, and model calibration. Medical Decision Making (2005) 25:633–645Crossref, Google Scholar
• Wu A. W., Rubin H. R., Mathews W. C., Ware J. E., Brysk L. T., Hardy W. D., Bozzette S. A., Spector S. A., Richman D. D. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Medical Care (1991) 29:786–798Crossref, Google Scholar
• Wu A. W., Matthews W. C., Brysk L. T., Atkinson J. H., Grant I., Abramson I., Kennedy C. J., McCutchan J. A., Spector S. A., Richman D. D. Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex. J. Acquired Immune Deficiency Syndromes (1990) 3:683–690Google Scholar